ACA
NKTR icon

Aptus Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Aptus Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,593
Closed -$708K – 549
2019
Q3 		$708K Buy
+2,593
New +$951K 0.04% 204

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Aptus Capital Advisors's NKTR Position: Q4 2019 in Review

Aptus Capital Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 2,593 shares — an estimated $708K sold.

Aptus Capital Advisors first reported a position in NKTR in Q3 2019 and held it in 1 quarter. The position peaked at $708K in Q3 2019. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Aptus Capital Advisors reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Aptus Capital Advisors sold 2,593 Nektar Therapeutics shares in Q4 2019, an estimated $708K.
  • Aptus Capital Advisors first reported a position in Nektar Therapeutics in Q3 2019 and held it in 1 quarter.
  • Aptus Capital Advisors's Nektar Therapeutics position peaked at $708K in Q3 2019.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Aptus Capital Advisors's 13F filing for Q4 2019, filed 10 Feb 2020.